Zoetis Inc. $ZTS is Southpoint Capital Advisors LP’s 2nd Largest Position

Southpoint Capital Advisors LP raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 340.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,200,000 shares of the company’s stock after acquiring an additional 1,700,000 shares during the period. Zoetis makes up 5.4% of Southpoint Capital Advisors LP’s holdings, making the stock its 2nd biggest holding. Southpoint Capital Advisors LP’s holdings in Zoetis were worth $260,062,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Prosperity Bancshares Inc acquired a new position in shares of Zoetis in the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in Zoetis in the 1st quarter valued at approximately $28,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis in the 4th quarter valued at approximately $30,000. Elyxium Wealth LLC purchased a new stake in Zoetis in the fourth quarter valued at approximately $32,000. Finally, Root Financial Partners LLC raised its position in Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In other news, Director Frank A. Damelio acquired 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders bought 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ZTS. Morgan Stanley lowered their target price on Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. HSBC cut their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average target price of $118.33.

Zoetis Price Performance

Shares of NYSE ZTS opened at $76.91 on Tuesday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company has a market cap of $32.24 billion, a price-to-earnings ratio of 12.75, a price-to-earnings-growth ratio of 1.18 and a beta of 0.75. The stock’s 50-day moving average is $77.27 and its two-hundred day moving average is $103.71. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $160.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the previous year, the business posted $1.48 earnings per share. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts forecast that Zoetis Inc. will post 6.87 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.